Suzette Moes
Protein scientist at the Biozentrum Basel's proteomics facility who, with Paul Jenö, carried out mass spectrometry for many mTOR studies from Michael Hall's lab
Proteomics Core Facility, Biozentrum, University of Basel (PubMed records 1995–2022)
Portrait: Biozentrum, University of Basel
Suzette Moes is a co-author of the 2017 Cancer Cell study in this Atlas (GUR2017) from Michael Hall's lab. In mice in which too much mTOR signalling causes fatty liver that progresses to liver cancer, the team found that mTORC2 drives the production of fatty acids and sphingolipids, a class of membrane fats. Blocking either kind of fat synthesis prevented tumours, and in human liver cancer samples high lipid synthesis went together with mTORC2 activity.
Moes's role in this and many other Basel papers was protein analysis by mass spectrometry. PubMed shows Moes working with Paul Jenö from at least 1995, when the two published a method for digesting proteins inside polyacrylamide gels to read their internal sequences, through work at the Biozentrum's proteomics facility on topics from mTOR signalling to maternal blood markers of Down syndrome (2009).
The PubMed record under this name and Basel runs to 2022. A current position could not be confirmed.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2017 | A | mTORC2 Promotes Tumorigenesis via Lipid Synthesis GUR2017 Co-author: contributed protein mass spectrometry to the mouse study showing that mTORC2 drives liver cancer through lipid synthesis. |
Co-authors in the Atlas 4
People with a profile here who share at least one study with Suzette Moes.
ShowHide
- Markus H. Heim Basel hepatologist who studies how the liver responds to viral infection and how liver cancer develops, and a co-author of the study linking mTORC2 to fat synthesis in liver tumours
- Michael N. Hall Discovered TOR in yeast in 1991 and established it as a central controller of cell growth that responds to nutrients. His lab later showed that TOR works in two distinct complexes, TORC1 and TORC2, only one of which is blocked by rapamycin
- Paul Jenoe Protein chemist who ran mass spectrometry and protein sequencing at the Biozentrum Basel for decades and contributed protein analysis to many mTOR studies from Michael Hall's lab
- Yakir Guri Showed mTORC2 drives liver cancer by rewiring lipid and sphingolipid synthesis
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.